Ideas & Impact › Resources › The Pediatric Treatment Gap
120,000 children

were newly infected with HIV.

50% of HIV-positive infants die

without timely treatment.

 

150,000 new infections

in adolescents (15-19 years), 66% of which were among girls.

~2.42 million children

aged 0-19 are living with HIV.

75,000 children (<15)

died from AIDS-related, equating to roughly 200 deaths daily.

Only 55%

of children living with HIV receive antiretroviral therapy, leaving ~620,000 untreated.

HIV positive children

are six times more likely to die

than adults without early diagnosis.

88% of children living with HIV,

83% of new infections, and 84% of AIDS-related deaths are in Sub-Saharan Africa.

Explore Related Resources

Search More Resources

Issue Briefs

Accelerating Progress to Ending Pediatric HIV

Published March 2026

We are at a critical inflection point for children affected by HIV. In 2024 alone, 120,000 children were newly infected, and, without timely treatment, half of HIV positive infants will not reach their second birthday. Children remain left behind—a child with HIV is 6 times more likely to die than an adult without timely diagnosis. […]

Topics:

HIV,

Pediatric HIV

Countries:

Global

Resource

Protecting Lives, Sustaining Progress

Published March 2026

The following landscape analysis of maternal and child health, HIV prevention, diagnosis, and treatment, and the historic strength of U.S. leadership in global aid provides an overview of these key areas of global health and recommendations for U.S. Congressional engagement and prioritization.

Topics:

Advocacy,

Children,

Global Health Security,

Health System Strengthening,

HIV,

Maternal and Child Health,

Mothers and Infants,

Women

Journal Articles

HIV Drug Resistance Profile in Clients Experiencing Treatment Failure After the Transition to a Dolutegravir-Based First-Line Antiretroviral Treatment Regimen in Mozambique

Published January 2025

Real-world data on HIV drug resistance (HIVDR) after transitioning to tenofovir disoproxil fumarate/lamivudine/dolutegravir (TLD) are limited. We assessed HIVDR rates and patterns in clients with virological failure (VF) after switching from an NNRTI-based regimen to TLD. A cross-sectional study was conducted in Gaza, Mozambique (August 2021–February 2022), including adults on first-line ART for ≥12 months […]

Topics:

HIV

Countries:

Mozambique